267 results match your criteria nhl survivors


Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.

Cancer 2019 12 30;125(24):4498-4508. Epub 2019 Aug 30.

University of Alabama at Birmingham, Birmingham, Alabama.

Background: Patients with non-Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE), particularly when they are receiving treatment. Blood or marrow transplantation (BMT) is recommended for relapsed/refractory NHL, and the risk of VTE after these patients undergo BMT is uncertain.

Methods: Patients with NHL who survived 2 years or longer after BMT were surveyed for long-term health outcomes, including VTE. Read More

View Article and Full-Text PDF
December 2019

Changes in life expectancy for cancer patients over time since diagnosis.

J Adv Res 2019 Nov 16;20:153-159. Epub 2019 Jul 16.

Editorial Board "Epidemiologia & Prevenzione", 20148 Milano, Italy.

The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985-2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. Read More

View Article and Full-Text PDF
November 2019

Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study.

J Clin Oncol 2019 10 8;37(28):2556-2570. Epub 2019 Jul 8.

St Jude Children's Research Hospital, Memphis, TN.

Purpose: The widely used, risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late effects remain understudied. We assessed late health outcomes after LMB treatment in the Childhood Cancer Survivor Study.

Patients And Methods: Multivariable regression models compared chronic health conditions, health status, and socioeconomic and neurocognitive outcomes between survivors of NHL treated with the LMB regimen (n = 126), survivors of NHL treated with non-LMB regimens (n = 444), and siblings (n = 1,029). Read More

View Article and Full-Text PDF
October 2019

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study.

Health Qual Life Outcomes 2019 Jul 2;17(1):115. Epub 2019 Jul 2.

Centre de Traitement des Données du Cancéropôle Nord-Ouest, Plateforme de Recherche Clinique Ligue Contre le Cancer, Centre François Baclesse, 3 Avenue Général Harris, 14076, Caen, Cedex 5, France.

Background: Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL). Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations. Read More

View Article and Full-Text PDF

Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.

Blood Adv 2019 07;3(13):1961-1969

Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD.

Infectious agents have been identified in the etiology of certain non-Hodgkin lymphoma (NHL) subtypes and solid tumors. The impact of this shared etiology on risk for second cancers in NHL survivors has not been comprehensively studied. We used US population-based cancer registry data to quantify risk of solid malignancies associated with infectious etiology among 127 044 adult 1-year survivors of the 4 most common NHL subtypes diagnosed during 2000 to 2014 (mean follow-up, 4. Read More

View Article and Full-Text PDF

Prognosis and cure of long-term cancer survivors: A population-based estimation.

Cancer Med 2019 08 17;8(9):4497-4507. Epub 2019 Jun 17.

Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy.

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure.

Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Read More

View Article and Full-Text PDF

Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma.

Chemotherapy 2019 22;64(1):36-41. Epub 2019 May 22.

Unit of Hematology, AUO Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.

Background: Fertility and gonadal function represent one of the most important aspects for long-term lymphoma survivors.

Aims: The aim of our study was to determine possible risk factors, such as age at treatment, chemotherapeutic regimen, protection with oral contraceptives (OCs), and gonadotropin-releasing hormone (GnRH) analogues in female patients treated for Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) at a reproductive age.

Methods: Patients between the age of 16 and 50 years at the time of HL or NHL diagnosis were selected. Read More

View Article and Full-Text PDF

Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.

J Med Econ 2019 Aug 30;22(8):742-750. Epub 2019 Apr 30.

c Department of Health Economics and Outcome Research , Sanofi , Shanghai , PR China.

To conduct a lifetime cost-effectiveness analysis (CEA) of rasburicase compared with standard of care (SOC) for tumor lysis syndrome (TLS) in children with hematologic malignancies from the Chinese healthcare system perspective. The CEA was performed using a decision tree model with a lifetime horizon. The model explores the cost-effectiveness of rasburicase vs SOC for both preventing TLS and treating established TLS among pediatric patients with acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and non-Hodgkin's lymphoma (NHL). Read More

View Article and Full-Text PDF

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.

Best Pract Res Clin Haematol 2019 03 16;32(1):47-53. Epub 2019 Feb 16.

Massey Cancer Center, Virginia Commonwealth University, Richmond VA, United States. Electronic address:

Treatment for Hodgkin (HL) and non-Hodgkin's lymphoma (NHL) has changed dramatically in the last fifty years. While there are increasing numbers of long-term survivors, there has been increasing recognition of the long-term toxicities of treatments, particularly therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML). The survival for t-MDS/AML is extremely poor. Read More

View Article and Full-Text PDF

Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.

Cancer 2019 07 22;125(13):2291-2299. Epub 2019 Mar 22.

French Center on eHealth, North-West Region Data Processing Center and French National League Against Cancer Clinical Research Platform, Caen, France.

Background: Long-term survivors of non-Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health-related quality of life. Little is known about the risk-to-benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long-term fatigue levels was investigated in a cross-sectional study. Read More

View Article and Full-Text PDF

Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.

Br J Haematol 2019 06 3;185(6):1099-1110. Epub 2019 Feb 3.

Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.

Progress in overall survival rates for childhood non-Hodgkin lymphoma (NHL) can be largely attributed to effective development and conduct of a number of international treatment studies. Knowledge gained from these studies has shifted the treatment paradigm from a "one-size fits all" strategy to a histologically dependent approach. More specifically, many now adhere to a risk-stratified approach, prescribing cumulative doses and intensities of chemotherapeutic exposures based upon the aggressiveness of disease. Read More

View Article and Full-Text PDF

Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.

Int J Hematol 2019 Apr 30;109(4):483-490. Epub 2019 Jan 30.

Department of Pediatrics, Yamagata University School of Medicine, Yamagata, Japan.

We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. Read More

View Article and Full-Text PDF

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood.

Acta Oncol 2019 May 30;58(5):753-762. Epub 2019 Jan 30.

a National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology , Oslo University Hospital , Oslo , Norway.

Chronic fatigue (CF) is scarcely explored among young adult cancer survivors (YACSs), and more knowledge is needed to develop targeted interventions for YACSs with CF. The present study aimed to investigate the prevalence of CF and associated factors in YACSs. Also, the change of fatigue with time was explored. Read More

View Article and Full-Text PDF

Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France.

JAMA Netw Open 2019 01 4;2(1):e187147. Epub 2019 Jan 4.

Health Product Epidemiology Department, French National Agency for Medicines and Health Products Safety, Saint-Denis, France.

Importance: Breast cancer survivors are at an increased risk of developing certain types of hematologic malignant neoplasm after diagnosis.

Objective: To estimate the incidence of various types of hematologic malignant neoplasm in breast cancer survivors, both in absolute terms and in association with the general population.

Design, Setting, And Participants: This nationwide cohort study conducted in France used data from the French National Health Data System, a database that contains all of French residents' health-related expenses. Read More

View Article and Full-Text PDF
January 2019

Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma.

JCO Clin Cancer Inform 2018 12;2:1-10

All authors: University of Pennsylvania, Philadelphia, PA.

Purpose: Multimodal treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) yields excellent outcomes; however, survivors are at risk of developing myriad late and long-term effects.

Methods: From a convenience sample of 964 survivors of HL (37%) and NHL (63%) using a publicly available Internet-based survivorship care plan (SCP) tool between 2011 and 2016, we examined patient-reported cancer care, toxicities, and survivorship care data.

Results: Of all survivors, 67% were female and 84% were white and 88% were free of cancer. Read More

View Article and Full-Text PDF
December 2018

Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction.

Int J Cancer 2018 11 21;143(10):2449-2457. Epub 2018 Sep 21.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses. It is unlikely that prior therapy is solely responsible for SPC risk. To investigate risk of SPC after diagnosis of non-Hodgkin lymphoma (NHL) and 10 of its subtypes we conducted a novel bidirectional analysis, SPCs after NHL and NHL as SPC. Read More

View Article and Full-Text PDF
November 2018

The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.

Biol Blood Marrow Transplant 2019 01 13;25(1):86-93. Epub 2018 Sep 13.

Medical Clinic V, University of Heidelberg, Heidelberg, Germany.

More than 60% of patients with non-Hodgkin lymphoma (NHL) are age >60 years at presentation. The purpose of this study was to compare the potential risks and benefits of allogeneic hematopoietic cell transplantation (alloHCT) in elderly patients with NHL with younger patients in a large sample, also taking into account comorbidity information. All patients age ≥18 years who had undergone alloHCT from a matched sibling or unrelated donor for NHL between 2003 and 2013 and were registered with the European Society for Blood and Marrow Transplantation were eligible for the study. Read More

View Article and Full-Text PDF
January 2019

Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors.

Curr Med Res Opin 2018 08 18;34(8):1529-1535. Epub 2018 May 18.

a Kite, A Gilead Company , Santa Monica , CA , USA.

Objective: Studies have shown that a proportion of patients with aggressive non-Hodgkin lymphoma (NHL) treated with standard chemotherapy will have long-term life expectancy comparable to those in the age-adjusted general population. This systematic literature review summarizes current literature regarding health-related quality of life (HRQoL) of long-term (≥2 years) survivors of aggressive NHL.

Methods: Electronic databases (without restriction on years) and abstracts from four major oncology and HRQoL conferences from 2014 to 2017 were searched. Read More

View Article and Full-Text PDF

Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.

Biol Blood Marrow Transplant 2018 08 15;24(8):1596-1601. Epub 2018 Mar 15.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address:

Autologous stem cell transplantation (ASCT) is a treatment option for HIV-positive patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, the prognosis after ASCT in HIV-positive Japanese patients remains unclear. The aim of this study was to evaluate the impact of HIV infection on transplant outcomes after ASCT in Japan. Read More

View Article and Full-Text PDF

Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study.

Expert Rev Anticancer Ther 2018 01 15;18(1):91-100. Epub 2017 Dec 15.

c Evidence Based Medicine Research Group & Faculty of Applied Sciences , Ton Duc Thang University , Ho Chi Minh City , Vietnam.

Background: Non-Hodgkin's lymphoma (NHL) survivors are at a higher risk of cardiovascular diseases (CVDs).

Methods: A population-based study was conducted to investigate the cardiovascular mortality trends to identify NHL survivors at the highest risk.

Results: The CVDs mortality was the second most common cause of death (13. Read More

View Article and Full-Text PDF
January 2018

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.

Cancer Res Treat 2018 Oct 9;50(4):1051-1063. Epub 2017 Nov 9.

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.

Purpose: We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL).

Materials And Methods: TheHRQOLwas assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to February 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire. We used linear mixed models to compare changes in HRQOL between indolent and aggressive NHL over time. Read More

View Article and Full-Text PDF
October 2018

Sleep quality and health-related quality of life among long-term survivors of (non-) Hodgkin lymphoma in Germany.

PLoS One 2017 6;12(11):e0187673. Epub 2017 Nov 6.

Institute for Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany.

This study investigated sleep quality and health-related quality of life (HRQOL) among long-term survivors of Hodgkin (HL) and non-Hodgkin lymphoma (NHL). The aim was to explore the impact of personal and health-related factors on sleep quality as well as associations between sleep quality and HRQOL. For the postal survey, participants with a minimum age of 18 years initially treated between 1998 and 2008 were recruited via the population-based cancer registry in Schleswig-Holstein, Northern Germany. Read More

View Article and Full-Text PDF
November 2017

Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.

J Clin Oncol 2017 Dec 18;35(34):3837-3843. Epub 2017 Sep 18.

Talya Salz, Emily C. Zabor, Nirupa J. Raghunathan, Matthew J. Matasar, Richard Steingart, and Andrew J. Vickers, Memorial Sloan Kettering Cancer Center, New York, NY; Peter de Nully Brown and Christoffer Johansen, Rigshospitalet; Susanne Oksberg Dalton and Christoffer Johansen, Danish Cancer Society Research Center, Copenhagen; Peter Svenssen Munksgaard, Aalborg University Hospital, Aalborg, Denmark; and Kevin C. Oeffinger, Duke University Medical Center, Durham, NC.

Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. Read More

View Article and Full-Text PDF
December 2017

Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma.

Cancer 2018 01 15;124(2):417-425. Epub 2017 Sep 15.

Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.

Background: Children with non-Hodgkin lymphoma (NHL) undergo treatment with central nervous system-directed therapy, the potentially neurotoxic effects of which have not been reported in NHL survivors.

Methods: NHL survivors (n = 187) participating in the St. Jude Lifetime Cohort who were 10 or more years from their diagnosis and were 18 years old or older underwent neurocognitive, emotional distress (Brief Symptom Inventory 18), and health-related quality of life (HRQOL) assessments (36-Item Short Form Health Survey). Read More

View Article and Full-Text PDF
January 2018

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.

J Hematol Oncol 2017 06 12;10(1):117. Epub 2017 Jun 12.

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Background: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL.

Methods: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens. Read More

View Article and Full-Text PDF

Sexual problems in male vs. female non-Hodgkin lymphoma survivors: prevalence, correlates, and associations with health-related quality of life.

Ann Hematol 2017 May 9;96(5):739-747. Epub 2017 Feb 9.

Division of Hematology-Oncology, Inha University Hospital and College of Medicine, Incheon, South Korea.

The objective of this study was to examine the prevalence and factors associated with sexual problems and their relationship to health-related quality of life (HRQOL) in male and female non-Hodgkin lymphoma (NHL) survivors. In this cross-sectional study, 738 NHL survivors (425 men and 313 women; mean time since diagnosis, 6.2 years) in South Korea completed the six-item instrument of adult sexual behavior used by the National Health and Social Life Survey in the United States. Read More

View Article and Full-Text PDF

Survival after subsequent non-Hodgkin's lymphoma and non-small cell lung cancer in patients with malignant thymoma.

J Thorac Dis 2016 Dec;8(12):3605-3613

Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.

Background: Survivors of malignant thymoma (MT) are at an increased risk of developing subsequent neoplasms. We compare overall survival (OS) between MT survivors who developed non-Hodgkin's lymphoma (NHL) or non-small cell lung cancer (NSCLC), and patients with first primary NHL (NHL-1) or NSCLC (NSCLC-1), respectively.

Methods: Using the population-based Surveillance, Epidemiology, and End Results (SEER) database for 1973 through 2013, 273,313 patients who had NHL-1, 21 patients with MT-NHL, 566,819 patients with NSCLC-1, and 38 patients with MT-NSCLC were identified. Read More

View Article and Full-Text PDF
December 2016

Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).

Br J Haematol 2017 04 20;177(2):226-242. Epub 2017 Jan 20.

Institute of Transfusion Medicine, Charité - University Hospital Berlin, Campus Virchow Clinic, Berlin, Germany.

The increased risk of subsequent primary malignancies (SPM) in survivors of adult-onset Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains a challenging clinical problem worldwide. The German cancer registry database, pooled from 14 federal states, was used to calculate the standardized incidence ratio (SIR) and excess absolute risk (EAR) of SPM in 128 587 patients registered with first primary HL/NHL between 1990 and 2012. Conversely, SIRs were also calculated for a subsequent HL/NHL following other first cancers. Read More

View Article and Full-Text PDF

Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.

J Control Release 2017 Oct 24;263:139-150. Epub 2016 Dec 24.

Department of Pharmaceutics and Pharmaceutical Chemistry, CCCD, University of Utah, Salt Lake City, UT 84112, USA; Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA. Electronic address:

Recently, we developed a new paradigm in macromolecular therapeutics that avoids the use of low molecular weight drugs. The activity of the "drug-free macromolecular therapeutics" is based on the biorecognition of complementary motifs at cell surface resulting in receptor crosslinking and apoptosis induction. The system is composed of two nanoconjugates: (1) a single-stranded morpholino oligonucleotide (MORF1) attached to an anti-CD20 Fab' fragment (Fab'-MORF1); (2) multiple copies of complementary oligonucleotide MORF2 grafted to a linear polymer of N-(2-hydroxypropyl)methacrylamide (HPMA) - P-(MORF2). Read More

View Article and Full-Text PDF
October 2017

Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study.

Pediatr Blood Cancer 2017 06 15;64(6). Epub 2016 Nov 15.

Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Background: Survivors of childhood non-Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors.

Method: Chronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data. Read More

View Article and Full-Text PDF